Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Wasif Saif

Showing results (461-470 of 473) with videos related to

Pageof 48
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 5, 2024
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemiaFaisal Inayat, Arslan Afzal, Muhammad Sajeel Anwar, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylaseMuhammad Wasif Saif, Glenda Black, Shalija Roy, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2016
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancerMuhammad Wasif Saif, James A Knost, E Gabriela Chiorean, et al.
Anti-Cancer Drugs|June 14, 2011
Triphendiol (NV-196), development of a novel therapy for pancreatic cancerXiaohong Wang, Robert McKernan, Ki H Kim, et al.
Cancer|September 14, 2016
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicityWen Wee Ma, Muhammad Wasif Saif, Bassel F El-Rayes, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumorsMuhammad Wasif Saif, Rohan Parikh, David Ray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancerDiane Lauren Reidy, Efsevia Vakiani, Marwan G Fakih, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairmentMuhammad Wasif Saif, Carlos R Becerra, Marwan G Fakih, et al.
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Pageof 48

Showing results (461-470 of 473) with videos related to

Sort By:
Pageof 48
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 5, 2024
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemiaFaisal Inayat, Arslan Afzal, Muhammad Sajeel Anwar, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylaseMuhammad Wasif Saif, Glenda Black, Shalija Roy, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2016
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancerMuhammad Wasif Saif, James A Knost, E Gabriela Chiorean, et al.
Anti-Cancer Drugs|June 14, 2011
Triphendiol (NV-196), development of a novel therapy for pancreatic cancerXiaohong Wang, Robert McKernan, Ki H Kim, et al.
Cancer|September 14, 2016
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicityWen Wee Ma, Muhammad Wasif Saif, Bassel F El-Rayes, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumorsMuhammad Wasif Saif, Rohan Parikh, David Ray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancerDiane Lauren Reidy, Efsevia Vakiani, Marwan G Fakih, et al.
Cancer Chemotherapy and Pharmacology|June 7, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairmentMuhammad Wasif Saif, Carlos R Becerra, Marwan G Fakih, et al.
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Pageof 48